COMPANY

SonALAsense, Inc.

Also known as SonALAsense · 4 sources

Location: Oakland, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Diffuse Intrinsic Pontine Glioma Diffuse Midline Glioma Recurrent GBM

Funding and NIH signals

NIH award NIH awarded $497K (SBIR Phase II 5R44CA275508-03, continuation, notice Sep 17, 2026). NIH RePORTER 5R44CA275508-03 (Sep 17, 2026)
Evidence (1 event)
- Sep 17, 2026 · NIH RePORTER 5R44CA275508-03
  Organization: SONALASENSE INC; City/State: San Carlos, CA; Project number: 5R44CA275508-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 497384; Administering IC: National Cancer Institute; Project title: Sonodynamic therapy using MRI-guided focused ultrasound in combination with 5-aminolevulinic acid to treat recurrent glioblastoma multiforme; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Sep 17, 2026 Grant Government grant — SBIR: $497,384 (annual award, as published), announced Sep 17, 2026. Agency: NIH/NCI. Source: government award database. source ↗
Sep 5, 2025 Grant Government grant — SBIR: $796,215 (annual award, as published), announced Sep 5, 2025. Agency: NIH/NCI. Source: government award database. source ↗
Feb 6, 2023 Trial start Phase 1/Phase 2: A Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Subjects With Recurrent GBM source ↗
Aug 12, 2022 Trial start 2: A Phase 2 Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Patients with DIPG source ↗

Last 2 years.

Sep 17, 2026 Government grant — SBIR: $497,384 (annual award, as published), announced Sep 17, 2026. Agency: NIH/NCI. Source: government award database. source ↗
Sep 5, 2025 Government grant — SBIR: $796,215 (annual award, as published), announced Sep 5, 2025. Agency: NIH/NCI. Source: government award database. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT05123534	A Phase 2 Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Patients with DIPG	2	Suspended	Aug 12, 2022	Jul 30, 2024 (actual)
NCT05370508	A Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Subjects With Recurrent GBM	Phase 1/Phase 2	Terminated	Feb 6, 2023	Jun 11, 2024 (actual)